{"id":"hb-01","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SIRT6, HB-01 aims to increase the expression of genes involved in cellular metabolism, potentially leading to improved glucose regulation and reduced inflammation.","oneSentence":"HB-01 is a small molecule that targets the SIRT6 protein to modulate cellular metabolism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:40:52.588Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05071430","phase":"PHASE2","title":"Safety and Efficacy of HB-1 for Panic Disorder","status":"COMPLETED","sponsor":"Honeybrains Biotech LLC","startDate":"2022-02-03","conditions":"Panic Disorder","enrollment":86},{"nctId":"NCT02837575","phase":"PHASE2","title":"Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine","status":"COMPLETED","sponsor":"Vical","startDate":"2016-09","conditions":"Herpes Genitalis","enrollment":261},{"nctId":"NCT02030301","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults","status":"COMPLETED","sponsor":"Vical","startDate":"2013-12","conditions":"Genital Herpes Simplex Type 2","enrollment":165},{"nctId":"NCT00391638","phase":"PHASE2, PHASE3","title":"Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2007-01","conditions":"Hepatitis B, HIV Infections","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Active Drug"],"phase":"phase_2","status":"active","brandName":"HB-01","genericName":"HB-01","companyName":"Honeybrains Biotech LLC","companyId":"honeybrains-biotech-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HB-01 is a small molecule that targets the SIRT6 protein to modulate cellular metabolism. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}